Oct 24 (Reuters) - Lyell Immunopharma Inc ( LYEL ):
* LYELL IMMUNOPHARMA TO ACQUIRE IMMPACT BIO AND PRIORITIZES
ITS
PIPELINE TO FOCUS ON NEXT-GENERATION CAR T-CELL THERAPIES
* LYELL IMMUNOPHARMA INC ( LYEL ): IS DISCONTINUING DEVELOPMENT OF
LYL797,
LYL845 AND EARLIER-STAGE TIL PROGRAMS
Source text for Eikon:
Further company coverage: